Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02023346 |
Recruitment Status
:
Active, not recruiting
First Posted
: December 30, 2013
Last Update Posted
: February 8, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Malignant Glioma | Behavioral: surveys and cognitive tests |
Study Type : | Observational |
Actual Enrollment : | 95 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Prognostic Awareness and Patient-Physician Communication in Malignant Glioma |
Actual Study Start Date : | December 2013 |
Estimated Primary Completion Date : | December 2019 |
Estimated Study Completion Date : | December 2019 |
Group/Cohort | Intervention/treatment |
---|---|
Malignant Glioma patients
This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
|
Behavioral: surveys and cognitive tests |
- measure prognostic awareness [ Time Frame: 2 years ]Prognostic awareness (PA) will be measured using the Chochinov Prognostic Awareness Scale. This scale classifies patients into three categories of awareness: full, limited, or no awareness.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Patient Inclusion Criteria
- Age greater than or equal to 18
- Diagnosis of any WHO grade III or IV glioma
- Admitted to the inpatient Neurology service
- Has had at least one outpatient visit with a neuro-oncologist at MSKCC Fluent in English
Caregiver Inclusion Criteria
- Age greater than or equal to 18
- Identified by the patient as a relative, friend, or partner with whom he or she has a significant relationship and who provides him or her physical or emotional assistance.
- The patient has himself or herself agreed to participate in this study
Exclusion Criteria:
Patient Exclusion Criteria
- A patient will be excluded if the Glasgow Coma Scale is less than 15. The patient must be oriented to self, age, place, and year, and month.
- Aphasia precluding comprehension and verbalization of consent to participate
- Patients who cannot verbally demonstrate their understanding of the risks, benefits, and alternatives to participating in the study. This evaluation will take place for otherwise eligible and willing participants, and it will be performed by the NP or MD clinician who is obtaining informed consent and will be documented in the medical record.
Caregiver Exclusion Criteria
- No eligible caregivers who can complete the brief assessment in person or via telephone will be excluded

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02023346
United States, New York | |
Memoral Sloan Kettering Cancer Center | |
New York, New York, United States, 10065 |
Principal Investigator: | Eli Diamond, MD | Memorial Sloan Kettering Cancer Center |
Additional Information:
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT02023346 History of Changes |
Other Study ID Numbers: |
13-253 |
First Posted: | December 30, 2013 Key Record Dates |
Last Update Posted: | February 8, 2018 |
Last Verified: | February 2018 |
Keywords provided by Memorial Sloan Kettering Cancer Center:
Patient-Physician Communication Brain cancer 13-253 |
Additional relevant MeSH terms:
Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |